Hodgkin's disease: Treatment of relapsed disease

Annals of Oncology

Volumn 13, Issue SUPPL. 4, 2002, Pages 159-162

  Cavalli, F G ^a  

^a OSPEDALE SAN GIOVANNI   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARABINOSIDE; BLEOMYCIN; CARMUSTINE; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FERRITIN ANTIBODY; FOLINIC ACID; GEMCITABINE; IFOSFAMIDE; IMMUNOTOXIN; LOMUSTINE; MELPHALAN; METHOTREXATE; MITOGUAZONE; MONOCLONAL ANTIBODY; NAVELBINE; PLATINUM DERIVATIVE; PREDNIMUSTINE; PREDNISONE; RADIOISOTOPE; RITUXIMAB; UNINDEXED DRUG; VINBLASTINE; VINDESINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; HODGKIN DISEASE; HUMAN; PRIORITY JOURNAL; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TREATMENT FAILURE;

EID: 0036434551     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf654     Document Type: Article

References (31)

1. Horning S. Hodgkin's disease. In Cavalli F, Hansen HH, Kaye S (eds): Textbook of Medical Oncology, 2nd edition. London: Martin Dunitz Publishers 2000; 461-474.
2. Diehl V, Mauch PM, Harris NL. Hodgkin's disease. In De Vita VT, Hellman S, Rosenberg SA (eds): Principles and Practice of Oncology, 6th edition. Lippincott Williams & Wilkins 2001; 2339-2386.
3. Canellos GP. New treatments for advanced Hodgkin's disease: an, uphill fight beginning close to the top. J Clin Oncol 2002; 20: 607-609.
4. Van Leeuwen FE, Klokmann WJ, Hagenbeek A. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol 1994; 12: 312-325.
5. Hansmann M, Fellbaum C, Hui P et al. Morphological and immunohistochemical investigation of non-Hodgkin's lymphoma combined with Hodgkin's disease. Histopathology 1989; 15: 35-48.
6. 18F-fluorodeoxyglucose for evaluation of residual mediastinal Hodgkin's disease. Blood 2001; 98: 2930-2934.
7. 18F-fluorodeoxyglucose (FDG-PET) after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others where additional therapy would mean avoidable toxicity? Leuk Lymphoma 2001; 42 (Suppl. 2): 65.
8. 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Leuk Lymphoma 2001; 42 (Suppl. 2): 65.
9. Roach MD, Brophy N, Cox R et al. Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease. J Clin Oncol 1990; 8: 623-629.
10. Mauch OP, Henry-Amar M. International Database on Hodgkin's disease: a cooperative effort to determine treatment outcome. Ann Oncol 1992; 3 (Suppl. 4): 59.
11. Fisher R, De Vita V, Hubbard S et al. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Intern Med 1979; 90: 761-763.
12. Wirth A, Corry J, Laidlaw C et al. Salvage radiotherapy for Hodgkin's disease following chemotherapy failure. Int J Radiat Oncol Biol Phys 1997; 39: 599-607.
13. Longo D, Duffey P, Young R et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992; 10: 210-218.
14. Bonfante V, Santoro A, Viviani S et al. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 1997; 15: 528-534.
15. Fermé C, Mounier N, Diviné M et al. Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Étude des Lymphomes de l'Adulte H89 Trial. J Clin Oncol 2002; 20: 467-475.
16. Josting A, Rueffer U, Franklin J et al. Prognostic factors and treatment outcome in primary progressive Hodgkin's lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000; 96: 1280-1286.
17. Andrè M, Henry-Amar M, Pico JL et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study J Clin Oncol 1999; 17: 222-229.
18. Reece DE, Barnett MJ, Shepherd JD et al. High-dose cyclophosphamide, carmustine, and etoposide with or without cisplatin and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood 1995; 86: 451-456.
19. Brice P, Diviné M, Simon D et al. Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD). Ann Oncol 1999; 10: 1485-1488.
20. Pfreundschuh M, Rueffer U, Lathan B et al. Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group. J Clin Oncol 1994; 12: 580-586.
21. Ferme C, Bastion Y, Lepage E et al. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Ann Oncol 1995; 6: 543.
22. Rodriguez J, Rodriguez MA, Fayad L et al. ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease. Blood 1999; 93: 3632-3636.
23. Josting A, Katay I, Rueffer U et al. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem-cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM). Ann Oncol 1998; 9: 289-295.
24. Brice P, Bouabdallah R, Moreau P et al. Prognostic factors for survival after high-dose therapy and autologous stem-cell transplantation from the French registry. Société Française de Greffe de Moëlle. Bone Marrow Transplant 1997; 20: 21-26.
25. Linch D, Winfield D, Goldstone A et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051-1054.
26. Schmitz N, Sextro M, Pfistner B. HDR-1: high-dose therapy (HDT) followed by hematopoietic stem-cell transplantation (HSCT) for relapsed chemosensitive Hodgkin's disease (HD): final results of a randomised GHSG and EBMT trial (HD-R1). Proc Am Soc Clin Oncol 1999; 18: 5.
27. Josting A, Franklin J, May M et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2002; 20: 221-230.
28. Devizzi L, Santoro A, Bonfante V et al. Vinorelbine: a new promising drug in Hodgkin's disease. Leuk Lymphoma 1996; 22: 409-414.
29. Santoro A, Bredenfield H, Devizzi L et al. Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicenter phase II study. J Clin Oncol 2000; 18: 2615-2619.
30. Vriesendorp H, Herpst J, Germack M et al. Phase I-II studies of yttrium-labelled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01. J Clin Oncol 1991; 9: 918-928.
31. Rassidakis GZ, Medeiros LJ, Viviani S et al. CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome. J Clin Oncol 2002; 20: 1278-1287.